New approach to treating chronic dystrophic cornea diseases

The efficiency of the treatment of dry eye disease patients with keratopathy at a subconjunctival injection of 1 % sodium hyaluronate was studied. This review describes the functions of hyaluronic acid depending on its molecular weight. The performed study shows the necessity of using the injection form of sodium hyaluronate in the treatment of patients with dry eye disease.

Download Full-text

Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease

Journal of Ophthalmology ◽

10.1155/2018/4691417 ◽

2018 ◽

Vol 2018 ◽

pp. 1-7 ◽

Cited By ~ 4

Author(s):

Klemens Fondi ◽

Piotr A. Wozniak ◽

Doreen Schmidl ◽

Ahmed M. Bata ◽

Katarzyna J. Witkowska ◽

...

Keyword(s):

Hyaluronic Acid ◽

Dry Eye ◽

Sodium Hyaluronate ◽

Signs And Symptoms ◽

Dry Eye Disease ◽

Eye Disease ◽

Quality Of Sleep ◽

Pro Re Nata ◽

Breakup Time

Purpose. This randomized, observer-masked, crossover study investigated the effect of two hyaluronic acid/trehalose-based containing formulations, with different physical properties, on the signs and symptoms in patients with moderate to severe dry eye disease (DED). Methods. In one group, patients received a mixture of sodium hyaluronate and trehalose (HT, Thealoz Duo®) for use during the day. In the other group, patients received a more viscous formulation consisting of hyaluronic acid, trehalose, and carbomer (HTC-gel, Thealoz Duo Gel) to use pro re nata. Both groups used HTC-gel before going to bed. Clinical standard tests for DED were performed at the beginning and end of each one-week period. Further, patient satisfaction including quality of sleep was assessed using a visual analogue scale. Results. Corneal fluorescein and conjunctival lissamine green staining scores decreased, and tear breakup time (BUT) increased for both groups (p<0.001 each). Mean instillation frequency was 3.1 ± 2.6 drops/day when using HT and 1.9 ± 2.2 drops/day when using HTC-gel (p=0.02). A significant improvement in the quality of sleep was observed with both treatments (p=0.01). Conclusions. Our results show improvement in signs and symptoms of DED in both groups. While instillation of HTC-gel resulted in a lower instillation frequency, both formulations of trehalose showed good clinical efficacy. This trial is registered with NCT02980913.

Download Full-text

Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study

Clinical Ophthalmology ◽

10.2147/opth.s177176 ◽

2018 ◽

Vol Volume 12 ◽

pp. 2499-2508 ◽

Cited By ~ 3

Author(s):

Marc Labetoulle ◽

Stefanie Schmickler ◽

David Galarreta ◽

Daniel Boehringer ◽

Abayomi Ogundele ◽

...

Keyword(s):

Hyaluronic Acid ◽

Clinical Study ◽

Dry Eye ◽

Dry Eye Disease ◽

Eye Disease ◽

Efficacy And Safety ◽

Hydroxypropyl Guar

Download Full-text

Crosslinked hyaluronic acid with liposomes and crocin for management symptoms of dry eye disease caused by moderate meibomian gland dysfunction

International Journal of Ophthalmology ◽

10.18240/ijo.2020.09.05 ◽

2020 ◽

Vol 13 (9) ◽

pp. 1368-1373

Author(s):

José-María Sánchez-González

Keyword(s):

Hyaluronic Acid ◽

Dry Eye ◽

Meibomian Gland ◽

Dry Eye Disease ◽

Meibomian Gland Dysfunction ◽

Eye Disease

Download Full-text

Efficacy of hyaluronic acid 0.3%, cyanocobalamin, electrolytes, and P-Plus in menopause patients with moderate dry eye disease

Graefe s Archive for Clinical and Experimental Ophthalmology ◽

10.1007/s00417-021-05415-6 ◽

2021 ◽

Author(s):

Concepción De-Hita-Cantalejo ◽

María Carmen Sánchez-González ◽

Carmen Silva-Viguera ◽

Marta C. García-Romera ◽

Ricardo Feria-Mantero ◽

...

Keyword(s):

Hyaluronic Acid ◽

Vitamin B12 ◽

Dry Eye ◽

Meibomian Gland ◽

Dry Eye Disease ◽

Eye Disease ◽

Eye Drops ◽

Phenol Red ◽

Prospective Longitudinal Study ◽

Prospective Longitudinal

Abstract Purpose To study the treatment efficacy of hyaluronic acid 0.3%, cyanocobalamin (vitamin B12), electrolytes, and P-Plus in menopausal patients with moderate dry eye disease. Methods Thirty female patients of mean age 53.06 ± 5.20 years (45–65) were enrolled in this prospective longitudinal study. Meibomian gland loss assessment was determined using a scale with four levels. The Ocular Surface Disease Index (OSDI) questionnaire, phenol red thread (PRT) test, and tear film break-up time (TFBUT) were also completed by the patients. Tear eye drops were formulated with 0.3 g of sodium hyaluronate, P-Plus ™, vitamin B12, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and SCO® (stabilized complex oxychloride). After 30 days, the patients were re-evaluated. Results The mean meibomian gland loss percentage was 37.97 ± 19.02 % (7.20 to 88.30%). Before treatment, the OSDI was 22.53 ± 14.03 score points (6.25 to 77.08). Posterior OSDI decreased to 16.26 ± 13.69 score points (0.00 to 70.83) (W = 58.00, P < 0.01). Before treatment, PRT was 10.31 ± 4.48 mm (4.00 to 21.00). Posterior PRT increased to 15.41 ± 6.27 mm (4.00 to 21.00) (W = 1520.50, P < 0.01). Before treatment, TFBUT was 6.23 ± 1.75 s (3.00 to 9.00). The posterior TFBUT increased to 8.10 ± 2.06 s (4.00 to 14.00) (W= 1382.50, P < 0.01). Conclusion The hyaluronic acid 0.3% and vitamin B12 eye drops effectively decreased dry eye symptoms in menopausal women and improved tear stability and volume.

Download Full-text

Crosslinked hyaluronic acid with liposomes and crocin for management symptoms of dry eye disease caused by moderate meibomian gland dysfunction

10.21203/rs.2.17536/v1 ◽

2019 ◽

Author(s):

José-María Sánchez-González ◽

Concepción De-Hita-Cantalejo ◽

María Carmen Sánchez-González

Keyword(s):

Hyaluronic Acid ◽

Dry Eye ◽

Meibomian Gland ◽

Dry Eye Disease ◽

Eye Disease ◽

Schirmer Test ◽

Ocular Surface Disease Index ◽

Artificial Tear ◽

Before And After ◽

Contralateral Eye

Abstract Background: To study the effect of uncrosslinked and crosslinked hyaluronic acid combined with other artificial tear components in patients with dry eye caused by moderate meibomian gland dysfunction.Method: Prospective, single-blind, contralateral eye study. Fifty eyes were analyzed (25 patients). Eye selection for each tear type was random, and the eye drop formulations Aquoral Forte® (artificial tear A) and Aquoral Lipo® (artificial tear B) were used. The determined dosing schedule was three times a day for six weeks, and the study participants underwent a clinical examination before and 45 days after lubricant treatment. The Schirmer test, tear breakup time (TBUT) test, and Ocular Surface Disease Index (OSDI) questionnaire were applied before and after instillation period with both types of artificial tears. Results: On the Schirmer test, a significant improvement was obtained with both tear A (p < 0.01) and tear B (p < 0.01). On the TBUT test, a significant improvement was obtained with tear A (p < 0.01) and tear B (p < 0.01). The OSDI score significantly decreased after instillation period with both artificial tear types (p < 0.01). Conclusion: Uncrosslinked hyaluronic acid combined with other components, such as tamarind seed polysaccharide, and crosslinked hyaluronic acid combined with liposomes and crocin are effective for management symptoms of dry eye disease.

Download Full-text